C4 therapeutics presents cemsidomide phase 1 data at the american society for hematology (ash) annual meeting that demonstrated potential to become best-in-class ikzf1/3 degrader

In multiple myeloma, cemsidomide in combination with dexamethasone at highest dose level explored to date achieved 36 percent overall response rate (orr) and 45 percent clinical benefit rate (cbr); responses seen across all dose levels

CCCC Ratings Summary

CCCC Quant Ranking